Minimal clinically important difference for asthma endpoints: an expert consensus report
Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management. The aim of the current expert consensus report is to provide a “state-of-the-a...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2020-06-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/29/156/190137.full |
| _version_ | 1819078653311451136 |
|---|---|
| author | Matteo Bonini Marcello Di Paolo Diego Bagnasco Ilaria Baiardini Fulvio Braido Marco Caminati Elisiana Carpagnano Marco Contoli Angelo Corsico Stefano Del Giacco Enrico Heffler Carlo Lombardi Ilaria Menichini Manlio Milanese Nicola Scichilone Gianenrico Senna Giorgio W. Canonica |
| author_facet | Matteo Bonini Marcello Di Paolo Diego Bagnasco Ilaria Baiardini Fulvio Braido Marco Caminati Elisiana Carpagnano Marco Contoli Angelo Corsico Stefano Del Giacco Enrico Heffler Carlo Lombardi Ilaria Menichini Manlio Milanese Nicola Scichilone Gianenrico Senna Giorgio W. Canonica |
| author_sort | Matteo Bonini |
| collection | DOAJ |
| description | Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors. |
| first_indexed | 2024-12-21T19:16:31Z |
| format | Article |
| id | doaj.art-4ddd949f3e72490fbf2001d7c48324b2 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-12-21T19:16:31Z |
| publishDate | 2020-06-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-4ddd949f3e72490fbf2001d7c48324b22022-12-21T18:53:03ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172020-06-012915610.1183/16000617.0137-20190137-2019Minimal clinically important difference for asthma endpoints: an expert consensus reportMatteo Bonini0Marcello Di Paolo1Diego Bagnasco2Ilaria Baiardini3Fulvio Braido4Marco Caminati5Elisiana Carpagnano6Marco Contoli7Angelo Corsico8Stefano Del Giacco9Enrico Heffler10Carlo Lombardi11Ilaria Menichini12Manlio Milanese13Nicola Scichilone14Gianenrico Senna15Giorgio W. Canonica16 National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, London, UK National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, London, UK Allergy and Respiratory diseases, University of Genoa, Dept of Internal Medicine (DiMI), Ospedale Policlinico San Martino, Genoa, Italy Dept of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy Allergy and Respiratory diseases, University of Genoa, Dept of Internal Medicine (DiMI), Ospedale Policlinico San Martino, Genoa, Italy Dept of Medicine, University of Verona, Verona, Italy Division of Respiratory Diseases, Dept of Medical and Surgical Sciences, University of Foggia, Italy Section of Internal and Cardiorespiratory Medicine, Dept of Medical Sciences, University of Ferrara, Ferrara, Italy Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation - Dept of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy Dept of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy Personalized Medicine, Asthma and Allergy - Humanitas Research Hospital, Rozzano, Italy Departmental Unit of Pneumology & Allergology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy Dept of Cardiovascular, Respiratory, Nephrology, Anaesthesiology and Geriatric Science, “Sapienza” University, Rome, Italy Division of Pulmonology, S Corona Hospital, Savona, Italy AOUP Policlinico Universitario, DIBIMIS, Università di Palermo, Palermo, Italy Dept of Medicine, University of Verona, Verona, Italy Personalized Medicine, Asthma and Allergy - Humanitas Research Hospital, Rozzano, Italy Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.http://err.ersjournals.com/content/29/156/190137.full |
| spellingShingle | Matteo Bonini Marcello Di Paolo Diego Bagnasco Ilaria Baiardini Fulvio Braido Marco Caminati Elisiana Carpagnano Marco Contoli Angelo Corsico Stefano Del Giacco Enrico Heffler Carlo Lombardi Ilaria Menichini Manlio Milanese Nicola Scichilone Gianenrico Senna Giorgio W. Canonica Minimal clinically important difference for asthma endpoints: an expert consensus report European Respiratory Review |
| title | Minimal clinically important difference for asthma endpoints: an expert consensus report |
| title_full | Minimal clinically important difference for asthma endpoints: an expert consensus report |
| title_fullStr | Minimal clinically important difference for asthma endpoints: an expert consensus report |
| title_full_unstemmed | Minimal clinically important difference for asthma endpoints: an expert consensus report |
| title_short | Minimal clinically important difference for asthma endpoints: an expert consensus report |
| title_sort | minimal clinically important difference for asthma endpoints an expert consensus report |
| url | http://err.ersjournals.com/content/29/156/190137.full |
| work_keys_str_mv | AT matteobonini minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT marcellodipaolo minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT diegobagnasco minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT ilariabaiardini minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT fulviobraido minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT marcocaminati minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT elisianacarpagnano minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT marcocontoli minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT angelocorsico minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT stefanodelgiacco minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT enricoheffler minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT carlolombardi minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT ilariamenichini minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT manliomilanese minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT nicolascichilone minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT gianenricosenna minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport AT giorgiowcanonica minimalclinicallyimportantdifferenceforasthmaendpointsanexpertconsensusreport |